Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.

Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.

“We believe icosabutate has the potential to impact the lives of millions of NASH patients globally” Rob de Ree

Chief Executive Officer, NorthSea Therapeutics

Voor meer informatie:

+31 (0) 35 760 65 05